Prudential Financial Inc. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 3,661,236 shares of the biopharmaceutical company’s stock after purchasing an additional 373,099 shares during the period. Prudential Financial Inc.’s holdings in Gilead Sciences were worth $296,632,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Keel Point LLC lifted its stake in shares of Gilead Sciences by 0.4% during the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 12 shares in the last quarter. Paradigm Financial Advisors LLC lifted its stake in Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 26 shares in the last quarter. Princeton Portfolio Strategies Group LLC lifted its stake in Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after purchasing an additional 41 shares in the last quarter. Auxier Asset Management lifted its stake in Gilead Sciences by 1.4% in the 2nd quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock worth $479,000 after purchasing an additional 96 shares in the last quarter. Finally, Edmonds Duncan Registered Investment Advisors LLC lifted its stake in Gilead Sciences by 1.6% in the 2nd quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock worth $452,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

Several brokerages have commented on GILD. Mizuho reiterated a “buy” rating and issued a $95.00 price target (up previously from $83.00) on shares of Gilead Sciences in a research note on Monday. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price target on the stock in a research note on Monday. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research note on Thursday, February 8th. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, February 7th. Finally, Citigroup reiterated a “buy” rating and issued a $105.00 price target (up previously from $103.00) on shares of Gilead Sciences in a research note on Thursday, February 8th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $87.04.

In related news, Director Gayle E. Wilson sold 60,000 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the transaction, the director now directly owns 182,258 shares in the company, valued at approximately $14,201,543.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the transaction, the insider now owns 3,070,099 shares in the company, valued at $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold a total of 418,333 shares of company stock worth $32,742,108 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $80.79 on Wednesday. The company has a current ratio of 3.55, a quick ratio of 3.48 and a debt-to-equity ratio of 1.10. The stock has a market cap of $104,684.40, a PE ratio of 9.38, a PEG ratio of -1.83 and a beta of 1.22. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.70 EPS. sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.24 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.82%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 59.77%.

COPYRIGHT VIOLATION NOTICE: “Prudential Financial Inc. Has $296.63 Million Position in Gilead Sciences, Inc. (GILD)” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://theolympiareport.com/2018/02/14/prudential-financial-inc-has-296-63-million-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.